This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
5up3
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Structure-Based Design of ASK1 Inhibitors as Potential First-in-Class Agents for Heart Failure== | ==Structure-Based Design of ASK1 Inhibitors as Potential First-in-Class Agents for Heart Failure== | ||
| - | <StructureSection load='5up3' size='340' side='right' caption='[[5up3]], [[Resolution|resolution]] 2.95Å' scene=''> | + | <StructureSection load='5up3' size='340' side='right'caption='[[5up3]], [[Resolution|resolution]] 2.95Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[5up3]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5UP3 OCA]. For a <b>guided tour on the structure components</b> use [http:// | + | <table><tr><td colspan='2'>[[5up3]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5UP3 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5UP3 FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=8GS:2-{6-[4-(propan-2-yl)-4H-1,2,4-triazol-3-yl]pyridin-2-yl}-2,3-dihydro-1H-isoindol-1-one'>8GS</scene></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=8GS:2-{6-[4-(propan-2-yl)-4H-1,2,4-triazol-3-yl]pyridin-2-yl}-2,3-dihydro-1H-isoindol-1-one'>8GS</scene></td></tr> |
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5uor|5uor]], [[5uox|5uox]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5uor|5uor]], [[5uox|5uox]]</td></tr> | ||
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Mitogen-activated_protein_kinase_kinase_kinase Mitogen-activated protein kinase kinase kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.25 2.7.11.25] </span></td></tr> | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Mitogen-activated_protein_kinase_kinase_kinase Mitogen-activated protein kinase kinase kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.25 2.7.11.25] </span></td></tr> | ||
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http:// | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5up3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5up3 OCA], [http://pdbe.org/5up3 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5up3 RCSB], [http://www.ebi.ac.uk/pdbsum/5up3 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5up3 ProSAT]</span></td></tr> |
</table> | </table> | ||
== Function == | == Function == | ||
| Line 24: | Line 24: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
[[Category: Mitogen-activated protein kinase kinase kinase]] | [[Category: Mitogen-activated protein kinase kinase kinase]] | ||
[[Category: Dougan, D R]] | [[Category: Dougan, D R]] | ||
Revision as of 08:20, 30 September 2020
Structure-Based Design of ASK1 Inhibitors as Potential First-in-Class Agents for Heart Failure
| |||||||||||
